Mergers & Acquisitions ·
PTC Therapeutics acquires Sangamo's ST-920 assets for $111M upfront plus up to $100M in milestones
SGMOQSangamo Therapeutics, Inc
Sangamo Therapeutics completed the sale of substantially all assets related to its ST-920 gene therapy candidate for Fabry disease to PTC Therapeutics on September 17, 2026. The transaction involves $111 million in upfront cash and up to $100 million in contingent milestone payments, plus assumption of specified liabilities. This sale follows Sangamo's Chapter 11 bankruptcy filing in June 2026 and a court-supervised auction process that selected PTC as the successful bidder on August 10, 2026. Concurrently, Nasdaq filed Form 25 to delist Sangamo's common stock, effective September 27, 2026, following the denial of its listing appeal in July 2026. The company operates in the biotechnology industry, focusing on gene therapy development.